TLT 101
Alternative Names: TLT-101Latest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator TikkunLev Therapeutics
- Class Cardiovascular therapies
- Mechanism of Action BIN1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dilated cardiomyopathy; Heart failure
Most Recent Events
- 11 Dec 2024 Preclinical trials in Heart failure in USA (IV)
- 11 Dec 2024 TikkunLev Therapeutics announces intention to submit IND to regulatory body for Dilated cardiomyopathy and Heart failure in December 2025
- 11 Dec 2024 Pharmacodynamics and adverse events data from a preclinical trial in Heart failure and Dilated cardiomyopathy released by TikkunLev Therapeutics